Trial size ARFGAP3 antibodies available in the Antibody Validation Project

Posted by M.Popov on 12th Nov 2020

Trial size ARFGAP3 antibodies available in the Antibody Validation Project

Trial size ARFGAP3 antibodies available in the Antibody Validation Project

Introduction:

ADP ribosylation factor GTPase activating protein 3, or more commonly known as ARFGAP3 is the protein product of the ARFGAP3 gene which is required for the dissociation of coat proteins from the Golgi. Apart from all the beneficial roles of this protein, it is partially responsible for both late-onset Parkison's disease as well as ALPS. Furthermore, recent studies showed that the ARFGAP3 gene can promote prostate cancer cell proliferation and migration in collaboration with paxillin. We provide a number of trial sized antibodies, which are suitable for ARFGAP3 research purposes, and to help you make the right decision and find the best suited antibody for you, please find the answers to some of the key topics regarding ARFGAP3 that we have provided in the links below.

What is ARFGAP3?

The protein encoded by this gene is a GTPase-activating protein (GAP) that associates with the Golgi apparatus and regulates the early secretory pathway of proteins. The encoded protein, named ADP ribosylation factor GTPase activating protein 3, promotes hydrolysis of ADP-ribosylation factor 1 (ARF1)-bound GTP, which is required for the dissociation of coat proteins from Golgi-derived membranes and vesicles. Dissociation of the coat proteins is a prerequisite for the fusion of these vesicles with target compartments and the activity of this protein is sensitive to phospholipids. 

Where is ARFGAP3 found?

Inside the cell, ARFGAP3 is found in the cytosol and the Golgi apparatus. It has cytoplasmic expression in several tissues, but the most abundant is in glandular cells.

What role does ARFGAP3 play in disease?

ARFGAP3 participates in the Parkinson's disease by binding to the mutated SNCA and and increasing its activity and regulating its toxicity. Higher concentrations of ARFGAP3 have been found in patients with ALPS and also ARFGAP3 is a novel androgen-regulated gene that can promote prostate cancer cell proliferation and migration in collaboration with paxillin.

ARFGAP3 antibodies in the Antibody Validation project

St John's Laboratory offers a variety of trial size primary antibodies which target ARFGAP3, which are available to try through the Antibody Validation Project. Below we highlight those which have already been reviewed, as well as others which are available to try.

Customer reviewed ARFGAP3 antibodies

ModelNameHostClonalityRatingApplication Tested
STJ91672ARF GAP3 antibodyRabbitPolyclonal5WB

Other ARFGAP3 antibodies available in the Antibody Validation Project

Currently we do not have any other ARFGAP3 antibodies available on the AVP.

ModelNameHostClonalityRecommended Applications
STJ110503Anti-ARFGAP3 AntibodyRabbitPolyclonalWB,IHC

How does the Antibody Validation Project work?

In order to help our customers with their choice of antibody with low risk, we offer one of the largest ranges of primary antibodies with trial size options available.

The Antibody Validation Project works like this.
1. Order your trial size antibody online.
2. Explore its suitability.
3. Return your results by posting them on the product page.
4. Receive a sample refund.

Find out more here.